Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines

OncoImmunology

Volumn 2, Issue 4, 2013, Pages

  Shirwan, Haval ^a,b   Sharma, Rajesh K ^b   Srivastava, Abhishek K ^a   Yolcu, Esma S ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Anticancer immunity; Cancer vaccines; CD137; Lung cancer; Sa 4 1bbl; Survivin

Indexed keywords

CANCER VACCINE; CD137 LIGAND; CD28 ANTIGEN; SUBUNIT VACCINE; SURVIVIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER ADJUVANT THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PLEIOTROPY;

EID: 84886943285     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23440     Document Type: Article

References (10)

1. Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs 2007; 8:1002-8; PMID:18058571
2. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9:271-85; PMID:19319144; http://dx.doi. org/10.1038/nri2526
3. Madireddi S, Schabowsky RH, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ. PLoS One 2012; 7:e42459; PMID:22870329; http://dx.doi.org/10.1371/journal.pone.0042459
4. Srivastava AK, Sharma RK, Yolcu ES, Ulker V, MacLeod K, Dinc G, et al. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. PLoS One 2012; 7:e48463; PMID:23144888; http://dx.doi.org/10.1371/journal. pone.0048463
5. Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, et al. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res 2010; 70:3945-54; PMID:20406989; http://dx.doi.org/10.1158/0008-5472.CAN-09-4480
6. Halstead ES, Mueller YM, Altman JD, Katsikis PD. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol 2002; 3:536-41; PMID:12021777; http://dx.doi.org/10.1038/ni798
7. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3:682-5; PMID:9176498; http://dx.doi.org/10.1038/nm0697-682
8. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006; 12:693-8; PMID:16680149; http://dx.doi. org/10.1038/nm1405
9. Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, Bandura-Morgan L, et al. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine 2009; 28:512-22; PMID:19836479; http://dx.doi.org/10.1016/j.vaccine.2009.09.127
10. Wang JC, Livingstone AM. Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J Immunol 2003; 171:6339-43; PMID:14662830